Pharmaceutical Research

, Volume 27, Issue 11, pp 2433–2445 | Cite as

Reliability of Inhibition Models to Correctly Identify Type of Inhibition

Research Paper



Type of inhibition (e.g. competitive, noncompetitive) is frequently evaluated to understand transporter structure/function relationships, but reliability of nonlinear regression to correctly identify inhibition type has not been assessed. The purpose was to assess the ability of nonlinear regression to correctly identify inhibition type.


This aim was pursued through three objectives that compared the competitive, noncompetitive, and uncompetitive inhibition models to best fit simulated competitive and noncompetitive data. The first objective involved conventional inhibition data and entailed simulated data for the common situation where substrate concentration was fixed at a single level but inhibitor concentration varied. The second objective involved Dixon-type data where both substrate and inhibitor concentrations varied. A third objective involved nonconventional inhibition data, where substrate concentration was varied and inhibitor was fixed at a single concentration. Experimental data were also examined.


Nonlinear regression performed poorly in identifying the correct inhibition model for conventional inhibition data, but performed moderately well for Dixon-type data. Interestingly, nonlinear regression performed well for nonconventional inhibition data, particularly at higher inhibitor concentrations. Experimental data support simulation findings.


Conventional inhibition data is a poor basis to determine inhibition type, while Dixon-type data affords modest success. Nonconventional inhibition data merits further consideration.


competitive inhibition dixon plot model noncompetitive inhibition transporter 



This work was supported in part by National Institutes of Health (grant DK67530). WinNonlin software was kindly donated by Pharsight Corp. (Mountain View, CA).

Supplementary material

11095_2010_236_MOESM1_ESM.docx (24 kb)
ESM 1 (DOCX 24 kb)


  1. 1.
    Rais R, Acharya C, Tririya G, Mackerell AD, Polli JE. Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter. J Med Chem. 2010;53:4749–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Gonzalez PM, Acharya C, Mackerell Jr AD, Polli JE. Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids. Pharm Res. 2009;26:1665–78.CrossRefPubMedGoogle Scholar
  3. 3.
    Zheng X, Ekins S, Raufman JP, Polli JE. Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm. 2009;6:1591.CrossRefPubMedGoogle Scholar
  4. 4.
    Diao L, Ekins S, Polli JE. Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res. 2009;26:1890–900.CrossRefPubMedGoogle Scholar
  5. 5.
    Lin CJ, Akarawut W, Smith DE. Competitive inhibition of glycylsarcosine transport by enalapril in rabbit renal brush border membrane vesicles: interaction of ACE inhibitors with high-affinity H+/peptide symporter. Pharm Res. 1999;16:609–15.CrossRefPubMedGoogle Scholar
  6. 6.
    Akarawut W, Lin CJ, Smith DE. Noncompetitive inhibition of glycylsarcosine transport by quinapril in rabbit renal brush border membrane vesicles: effect on high-affinity peptide transporter. J Pharmacol Exp Ther. 1998;287:684–90.PubMedGoogle Scholar
  7. 7.
    Lau AJ, Chang TK. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols. Drug Metab Dispos. 2009;37:1931–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Frank H and Althoen S, C. Statistics: concepts and applications. 1994; 853.Google Scholar
  9. 9.
    Akaike A. Posterior probabilities for choosing a regression model. Annals of the Institute of Mathematical Statistics. 1978;30A9–14.Google Scholar
  10. 10.
    Bhattacharyya A, Mazumdar Leighton S, Babu CR. Bioinsecticidal activity of Archidendron ellipticum trypsin inhibitor on growth and serine digestive enzymes during larval development of Spodoptera litura. Comp Biochem Physiol C Toxicol Pharmacol. 2007;145:669–77.CrossRefPubMedGoogle Scholar
  11. 11.
    Ismair MG, Kullak-Ublick GA, Blakely RD, Fried M, Vavricka SR. Tegaserod inhibits the serotonin transporter SERT. Digestion. 2007;75:90–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Je JY, Kim SK. Water-soluble chitosan derivatives as a BACE1 inhibitor. Bioorg Med Chem. 2005;13:6551–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Martin-Venegas R, Rodriguez-Lagunas MJ, Geraert PA, Ferrer R. Monocarboxylate transporter 1 mediates DL-2-Hydroxy-(4-methylthio)butanoic acid transport across the apical membrane of Caco-2 cell monolayers. J Nutr. 2007;137:49–54.PubMedGoogle Scholar
  14. 14.
    Narawa T, Tsuda Y, Itoh T. Chiral recognition of amethopterin enantiomers by the reduced folate carrier in Caco-2 cells. Drug Metab Pharmacokinet. 2007;22:33–40.CrossRefPubMedGoogle Scholar
  15. 15.
    Wong IL, Chan KF, Tsang KH, Lam CY, Zhao Y, Chan TH, et al. Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives. J Med Chem. 2009;52:5311–22.CrossRefPubMedGoogle Scholar
  16. 16.
    Kakkar T, Boxenbaum H, Mayersohn M. Estimation of Ki in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab Dispos. 1999;27:756–62.PubMedGoogle Scholar
  17. 17.
    Schlamowitz M, Shaw A, Jackson WT. Limitations of the Dixon plot for ascertaining naure of enzyme inhibition. Tex Rep Biol Med. 1969;27:483–8.PubMedGoogle Scholar
  18. 18.
    Duan P, You G. Novobiocin is a potent inhibitor for human organic anion transporters. Drug Metab Dispos. 2009;37:1203–10.CrossRefPubMedGoogle Scholar
  19. 19.
    Lan T, Rao A, Haywood J, Davis CB, Han C, Garver E, et al. Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides. Drug Metab Dispos. 2009;37:2375–82.CrossRefPubMedGoogle Scholar
  20. 20.
    Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, et al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008;327:432–41.CrossRefPubMedGoogle Scholar
  21. 21.
    Rais R, Gonzalez PM, Zheng X, Wring SA, Polli JE. Method to screen substrates of apical sodium-dependent bile acid transporter. AAPS J. 2008;10:596–605.CrossRefPubMedGoogle Scholar
  22. 22.
    Balakrishnan A, Polli JE. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm. 2006;3:223–30.CrossRefPubMedGoogle Scholar
  23. 23.
    Craddock AL, Love MW, Daniel RW, Kirby LC, Walters HC, Wong MH, et al. Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998;274:G157–69.PubMedGoogle Scholar
  24. 24.
    Balakrishnan A, Sussman DJ, Polli JE. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm Res. 2005;22:1269–80.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.University of Maryland School of PharmacyBaltimoreUSA

Personalised recommendations